ArticleExpert opinion on pharmacotherapy

Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy.

Efrat Luttwak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.